Statements (17)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:administeredBy |
intravenous injection
|
| gptkbp:alternativeName |
eribulin mesylate
|
| gptkbp:approvedBy |
liposarcoma
metastatic breast cancer |
| gptkbp:ATCCode |
L01XX41
|
| gptkbp:brand |
gptkb:Halaven
|
| gptkbp:CASNumber |
441045-17-6
|
| gptkbp:clinicalTrialPhase |
Phase III
|
| gptkbp:developedBy |
gptkb:Eisai_Co.,_Ltd.
|
| gptkbp:FDAApproved |
yes
|
| gptkbp:hasMolecularFormula |
C40H59NO11·CH4O3S
|
| https://www.w3.org/2000/01/rdf-schema#label |
E7438
|
| gptkbp:mechanismOfAction |
microtubule dynamics inhibitor
|
| gptkbp:usedFor |
gptkb:cancer
|
| gptkbp:bfsParent |
gptkb:tazemetostat
|
| gptkbp:bfsLayer |
8
|